Denise M. Lowe
Imperial College London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Denise M. Lowe.
FEBS Letters | 1991
Denise M. Lowe; Vanita Parmar; Sharon D. Kemp; Brendan A. Larder
Two conserved sequence motifs, occurring in HIV‐1 reverse transcriptase at residues 110–116 and 183–190, have been studied using site‐directed mutagenesis of the cloned gene. In particular, aspariates at positions 185 and 186 have each been mutated to either asparagine or glutamate. The resulting mutant proteins were catalytically inactive but still able to bind the template‐primer complex, poly rA‐oligo dT. Other mutations in these regions results in reduced reverse transcriptase activity but the mutation of tyrosine‐183 to serine caused a significant increase in the Km for dTTP and the Km for inhibition by 3′‐azi‐Jothymidine‐triphosphate, 2′3′‐dideoxythymidine‐triphosphate and phosphonoformic acid.
British Journal of Cancer | 1998
Robin A. F. Crawford; C. J. Caldwell; Ray K. Iles; Denise M. Lowe; John H. Shepherd; Tim Chard
bcl-2 is one of a family of genes that control the apoptotic threshold of a cell. bcl-2 protein and its anti-apoptotic homologue, mcl-1, with the pro-apoptotic protein, bax, are thought to function by forming homo- and heterotypic dimers that then control the progression to apoptosis. p53 is also involved as a down-regulator of bcl-2 and a promoter of bax. To determine the effect of these apoptotic mechanisms, we used immunohistochemistry to determine the prognostic significance of the expression of bcl-2, mcl-1, bax and p53 in primary and recurrent cervical cancer. Tissues from 46 patients with primary cervical cancer and 28 women with recurrent carcinoma were stained for bcl-2, mcl-1, bax and p53. Kaplan-Meier survival analysis was performed using the log-rank test for differences between groups. In the primary disease group, positive staining for bcl-2 was associated with a better 5-year survival (bcl-2 +ve, 84% vs bcl-2 -ve, 53%, P = 0.03). Positive staining for p53 was associated with a survival disadvantage (p53 +ve, 4-year survival 38% vs p53 -ve, 4-year survival 78%, P = 0.02). mcl-1 and bax staining were not useful as prognostic indicators in primary disease. No marker was prognostic in recurrent disease. Positive bcl-2 staining defines a group of patients with primary disease with a good prognosis. p53, an activator of the bax promoter, identifies a group with a worse outcome. In recurrent disease, none of the markers reflected prognosis.
Journal of Crystal Growth | 1993
E.Y. Jones; David I. Stuart; Elspeth F. Garman; R. Griest; D.C. Phillips; G.L. Taylor; O. Matsumoto; Graham Darby; Brendan A. Larder; Denise M. Lowe; Kenneth L. Powell; Dorothy J.M. Purifoy; C. Ross; Donald O’N Somers; Margaret Tisdale; David K. Stammers
Abstract Extensive studies on the crystallization of HIV-1 reverse transcriptase (RT) have yielded several crystal forms, two of which show diffraction to minimum Bragg spacings of 6 A or better. Type 1 crystals belong to the space group P2 1 2 1 2 1 with unit cell dimensions a = 147 A , b = 190 A and c = 182 A . Crystal density measurement indicate a very high crystal solvent content of 77% consistent with the presence of two RT heterodimers (66k/51k) per crystallographic asymmetric unit. These crystals are suitable for a low resolution determination of the apoenzyme structure. The second well ordered crystal form (space group P4 2 22 with unit cell dimensions a = b = 120 A , c = 320 A ) results from the co-crystallization of RT heterodimer and a double-stranded DNA oligonucleotide. Crystal density measurements again yield a relatively high value for the solvent content (7%; one RT heterodimer per crystallographic asymmetric unit) and elemental analysis indicates that one DNA oligonucleotide is associated with each RT heterodimer. This is consistent with each heterodimer possessing a single, competent, active site.
Journal of Clinical Pathology | 1994
Thomas Ind; Ray K. Iles; Paul G. Carter; Denise M. Lowe; John H. Shepherd; Christopher Hudson; Tim Chard
AIM--To investigate serum placental-type alkaline phosphatase (PLAP-type) activities in women with squamous and glandular malignancies of the reproductive tract using an immunoradiometric assay. METHODS--PLAP-type immunoreactivity was measured in 180 women with non-ovarian malignancies of the reproductive tract and the values were compared with those from 334 controls. The cases comprised 18 vulval, nine vaginal, 103 cervical, 46 endometrial, and five fallopian tube cancers. RESULTS--Serum PLAP-type activities were no different from controls in patients with squamous cell tumours. Women with adenocarcinoma of the cervix, endometrium, and fallopian tube had increased values: women with endometrial cancer had a median value nearly four times greater than that of controls. There was no direct correlation between PLAP-type activities and stage of disease in patients with endometrial cancer, but values reverted to normal after treatment. CONCLUSIONS--Serum PLAP-type measurements are of no value in the management of patients with squamous cell tumours of the female reproductive tract. Raised activities can, however, be found in glandular tumours, in particular endometrial cancer where serum PLAP-type measurements may be of value in predicting remission.
Biochimie | 1985
Hugues Bedouelle; Paul Carter; Mary M. Y. Waye; Greg Winter; Denise M. Lowe; Anthony J. Wilkinson; Alan R. Fersht
The gene encoding the enzyme tyrosyl tRNA synthetase from Bacillus stearothermophilus has been systematically altered using synthetic oligonucleotides as mutagens. The construction of mutations has been facilitated by using strains of bacteria defective in mismatch repair and also by utilising a genetic marker in the M13 strain (such as an amber mutation, or an EcoK or EcoB site) which allows selection for the progeny of M13 replication derived from the minus (mutagenized) strand. Several mutations have been constructed in the ATP binding site to elucidate the roles of individual residues in catalysis and substrate binding and it has even been possible to construct mutants which have improved affinity for ATP. Mutations in various surface lysine and arginine residues have allowed us to identify potential contacts with the tRNA, and indicate that a cluster of basic residues close to the C-terminus of the enzyme probably makes important interactions with the tRNA.
Nature | 1985
Alan R. Fersht; Jian‐Ping Shi; J.W. Knill-Jones; Denise M. Lowe; Anthony J. Wilkinson; David M. Blow; Peter Brick; Paul Carter; Mary Miu Yee Waye; Greg Winter
Biochemistry | 1988
Denise M. Lowe; Alastair Aitken; Christopher Bradley; Graham Darby; Brendan A. Larder; Kenneth L. Powell; Dorothy J.M. Purifoy; Margaret Tisdale; David K. Stammers
Biochemistry | 1985
Denise M. Lowe; Alan R. Fersht; Anthony J. Wilkinson; Paul Carter; Greg Winter
Biochemistry | 1986
Michael D. Jones; Denise M. Lowe; Thor J. Borgford; Alan R. Fersht
Biochemistry | 1987
Denise M. Lowe; Greg Winter; Alan R. Fersht